Absence Epilepsy
Neurology·MeSH: Epilepsy, Absence
Prevalence
700.0 / 100K
Incidence
48.0 / 100K/yr
2 drugs in development·2 companies·1 clinical trial
Drug Pipeline by Phase
Phase 2(1)
| Drug | Company |
|---|---|
| BMB-101 | BRIGHT MINDS BIOSCIENCES INC. (DRUG) |
Preclinical(1)
| Drug | Company |
|---|---|
| BAER-101 | AVENUE THERAPEUTICS, INC. (ATXI) |
Compare drugs
Frequently asked questions
How many drugs are in development for Absence Epilepsy?
BioSniper tracks 2 drugs in development for Absence Epilepsy across 2 companies.
How many clinical trials target Absence Epilepsy?
There are 1 clinical trial targeting Absence Epilepsy tracked by BioSniper.
What is the prevalence of Absence Epilepsy?
The estimated prevalence of Absence Epilepsy is approximately 700.0 per 100,000 population.
Deep-dive into Absence Epilepsy
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis